STEVANATO-GROUP
Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus® auto-injector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005581/en/
The agreement makes Stevanato Group an exclusive manufacturing partner for the device, offering a full set of capabilities to its pharmaceutical customers. Stevanato Group will mould the components for Aidaptus® and provide final and sub-assembly equipment, while also offering market-leading pre-filled syringes to enable pharmaceutical customers to create the final product for patient use. Assembly of the components will be undertaken by both Stevanato Group at its global manufacturing sites and by Owen Mumford at its automated assembly center of excellence in the UK.
The collaboration is intended to bring added value to customers, matching world-class device expertise with premium manufacturing capabilities. It is expected to streamline device production with the aim to and deliver the full value of the innovative Aidaptus® platform to the market.
Aidaptus® is a 2-step, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features plunger sensing technology with a self-adjusting plunger rod that automatically adapts to the individual plunger positions and different fill volumes in each syringe, with no change parts required. The auto-injector is also able to accommodate a unique variety of drug viscosities.
With over 70 years of experience, Stevanato Group supports pharmaceutical companies with the right degree of flexibility to meet their quality and productivity goals. With an integrated offer of precision injection moulding capabilities and modular assembly platforms, the company offers the possibility to scale production and move from clinical trial to high-volume production with extreme flexibility.
“Aidaptus® will help patients to self-administer their individual therapies using a simple and easy to use device,” said Adam Mumford, Director of Owen Mumford. “At the same time, this auto-injector can help reduce complexity, minimize supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies, thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes. Often during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well.”
Mauro Stocchi, Chief Business Officer of Stevanato Group, commented: "We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market. As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors. With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems."
“Stevanato Group is an established company with an excellent reputation in the pharmaceutical industry,” said Michael Earl, Director of Pharmaceutical Services at Owen Mumford. “It has deep expertise in complex moulding and assembly operations and will be a reliable source of quality components for our Aidaptus® auto-injector. Forming a collaboration with Stevanato Group will provide additional reach to enable more customers to benefit from the advantages of this innovative new platform.”
Steven Kaufman, VP for Drug Delivery Systems at Stevanato Group, added: "The Aidaptus® auto-injector platform combines ease of use for patients with faster time-to-market access for pharma organizations. We aim to be the strategic partner with which to develop innovative combination products as we continue the expansion of our integrated capabilities in the drug delivery space, and for this reason we are very excited to work with Owen Mumford and provide access to its exciting new auto-injector platform."
The collaboration will be jointly launched at Pharmapack 2022. Stevanato Group will be pleased to present Aidaptus® and its portfolio of integrated solutions on May 18 and 19 at Pharmapack Europe, Paris Expo, booths no. B56 and B58.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients. To learn more, visit stevanatogroup.com.
Forward-Looking Statements
This press release may include forward-looking statements. The words "aim", "opportunities" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs, or current expectations concerning, among other things, the Company's product offering, the potential use of the Company's products to treat different diseases, growth opportunities, market position, and the expansion of the Company's integrated capabilities. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators, and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005581/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 11:17:00 CEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom